<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48395">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01651728</url>
  </required_header>
  <id_info>
    <org_study_id>48/PT02.FK/ETIK/2012</org_study_id>
    <secondary_id>U1111-1133-2403</secondary_id>
    <nct_id>NCT01651728</nct_id>
  </id_info>
  <brief_title>Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients</brief_title>
  <official_title>Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients: A Study of Immunological, Inflammatory, and Coagulation Responses in Relation to Reduce Mortality During Hospitalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <authority>Indonesia: Departement Kesehatan (Department of Health)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to assess the effect of simvastatin on immunology, inflammatory, and
      coagulation responses, and mortality in elderly with pneumonia based. The primary outcome is
      mortality event.

      The hypothesis of this study is that simvastatin therapy will reduce mortality in elderly
      with pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elderly patients diagnosed with pneumonia after getting information and signing informed
      consent will be included in this trial. Simvastatin 20 mg will be administered to
      intervention group, while control group will receive placebo. Both groups will receive drugs
      (or placebo) for 30 days.

      Baseline data will be collected within 24 hours after admission. Then the subject will be
      followed up for 30 days. At the 7th day, patients will be underwent several laboratory
      tests, i.e. serum TNF-α (Tumor Necrosis Factor alpha), IFN-ϒ Interferon gamma), CRP
      (C-Reactive Protein), and PAI-1 (Plasminogen Activator Inhibitor-1). Death from all causes
      until 30 days will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TNF-α (Tumor Necrosis Factor alpha) concentration</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Interferon-gamma (INF-ϒ) concentration</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Plasminogen Activator Inhibitor-1 (PAI-1) concentration</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-Reactive Protein (CRP) concentration</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Community-Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet 20 mg once daily for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet once daily for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Tablet 20 mg once daily for 30 days</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>CAS Number 79902-63-9</other_name>
    <other_name>ATC Code C10AA01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>daily for 30 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elderly patients with pneumonia

        Exclusion Criteria:

          -  Severe septic condition

          -  Hepatic Cirrhosis

          -  Acute coronary disease

          -  Total cholesterol which is too high or too low

          -  In anticoagulant therapy

          -  In steroid therapy or other immunosuppressant therapy

          -  Have refused to join the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuntjoro Harimurti, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kuntjoro Harimurti, MD</last_name>
    <phone>+628159792380</phone>
    <email>kuntjoro.harimurti01@ui.ac.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>Jakarta</state>
        <zip>10340</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuntjoro Harimurti, MD</last_name>
      <phone>+628159792380</phone>
      <email>kuntjoro.harimurti01@ui.ac.id</email>
    </contact>
    <investigator>
      <last_name>Kuntjoro Harimurti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Dublin S, Jackson ML, Nelson JC, Weiss NS, Larson EB, Jackson LA. Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ. 2009 Jun 16;338:b2137. doi: 10.1136/bmj.b2137.</citation>
    <PMID>19531550</PMID>
  </reference>
  <reference>
    <citation>Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sørensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med. 2008 Oct 27;168(19):2081-7.</citation>
    <PMID>18955636</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 2, 2012</lastchanged_date>
  <firstreceived_date>July 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Kuntjoro Harimurti</investigator_full_name>
    <investigator_title>M.D., M.Sc.</investigator_title>
  </responsible_party>
  <keyword>Simvastatin</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Elderly</keyword>
  <keyword>TNF-α</keyword>
  <keyword>IFN-ϒ</keyword>
  <keyword>PAI-1</keyword>
  <keyword>CRP</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
